Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.17
MYL's Cash to Debt is ranked lower than
89% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.46 vs. MYL: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.64 Max: 38.64
Current: 0.17
0.03
38.64
Equity to Asset 0.44
MYL's Equity to Asset is ranked lower than
75% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. MYL: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.61 Max: 0.9
Current: 0.44
0.19
0.9
Interest Coverage 4.30
MYL's Interest Coverage is ranked lower than
78% of the 458 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.68 vs. MYL: 4.30 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.61 Max: 9.19
Current: 4.3
0.83
9.19
F-Score: 6
Z-Score: 2.15
M-Score: -2.32
WACC vs ROIC
9.83%
8.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.49
MYL's Operating margin (%) is ranked higher than
72% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. MYL: 15.49 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s Operating margin (%) Range Over the Past 10 Years
Min: 5.8  Med: 16.36 Max: 26.53
Current: 15.49
5.8
26.53
Net-margin (%) 8.99
MYL's Net-margin (%) is ranked higher than
61% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. MYL: 8.99 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s Net-margin (%) Range Over the Past 10 Years
Min: -3.53  Med: 9.01 Max: 14.68
Current: 8.99
-3.53
14.68
ROE (%) 10.22
MYL's ROE (%) is ranked higher than
60% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. MYL: 10.22 )
Ranked among companies with meaningful ROE (%) only.
MYL' s ROE (%) Range Over the Past 10 Years
Min: -14.72  Med: 14.57 Max: 29.99
Current: 10.22
-14.72
29.99
ROA (%) 4.06
MYL's ROA (%) is ranked higher than
51% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.85 vs. MYL: 4.06 )
Ranked among companies with meaningful ROA (%) only.
MYL' s ROA (%) Range Over the Past 10 Years
Min: -2.47  Med: 4.61 Max: 9.21
Current: 4.06
-2.47
9.21
ROC (Joel Greenblatt) (%) 22.86
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.64 vs. MYL: 22.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.9  Med: 31.19 Max: 47.2
Current: 22.86
17.9
47.2
Revenue Growth (3Y)(%) 5.40
MYL's Revenue Growth (3Y)(%) is ranked lower than
52% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. MYL: 5.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.1  Med: 15.20 Max: 54.5
Current: 5.4
-6.1
54.5
EBITDA Growth (3Y)(%) 5.20
MYL's EBITDA Growth (3Y)(%) is ranked lower than
57% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. MYL: 5.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.4  Med: 11.20 Max: 107.9
Current: 5.2
-20.4
107.9
EPS Growth (3Y)(%) 3.80
MYL's EPS Growth (3Y)(%) is ranked lower than
57% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.40 vs. MYL: 3.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.1  Med: 3.80 Max: 110.4
Current: 3.8
-29.1
110.4
» MYL's 10-Y Financials

Financials (Next Earnings Date: 2016-05-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

MYL Guru Trades in Q2 2015

Kyle Bass 780,251 sh (New)
Larry Robbins 1,815,874 sh (New)
John Keeley 37,050 sh (New)
David Tepper 989,528 sh (New)
Louis Moore Bacon 210,000 sh (New)
Eric Mindich 1,456,404 sh (New)
Jim Simons 548,006 sh (New)
Steven Cohen 1,331,200 sh (+425.54%)
Mario Gabelli 33,250 sh (+232.50%)
John Paulson 21,913,061 sh (+46.59%)
Tom Russo 5,850 sh (unchged)
Vanguard Health Care Fund 15,891,898 sh (unchged)
George Soros 160,000 sh (unchged)
First Eagle Investment Sold Out
Joel Greenblatt Sold Out
Scott Black 185,573 sh (-1.06%)
Pioneer Investments 631,760 sh (-23.54%)
Paul Tudor Jones 12,766 sh (-88.34%)
» More
Q3 2015

MYL Guru Trades in Q3 2015

Jim Simons 1,716,741 sh (+213.27%)
Mario Gabelli 67,250 sh (+102.26%)
John Keeley 56,120 sh (+51.47%)
Vanguard Health Care Fund 23,262,875 sh (+46.38%)
Tom Russo 5,850 sh (unchged)
John Paulson 21,913,061 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Eric Mindich Sold Out
Scott Black 180,575 sh (-2.69%)
Paul Tudor Jones 10,768 sh (-15.65%)
Pioneer Investments 365,302 sh (-42.18%)
Larry Robbins 934,006 sh (-48.56%)
David Tepper 470,071 sh (-52.50%)
Louis Moore Bacon 80,000 sh (-61.90%)
Steven Cohen 360,900 sh (-72.89%)
Kyle Bass 78,905 sh (-89.89%)
» More
Q4 2015

MYL Guru Trades in Q4 2015

Joel Greenblatt 9,029 sh (New)
David Einhorn 2,890,000 sh (New)
David Tepper 853,749 sh (+81.62%)
Pioneer Investments 469,785 sh (+28.60%)
Vanguard Health Care Fund 24,253,075 sh (+4.26%)
John Paulson 22,794,061 sh (+4.02%)
Steven Cohen 1,000,000 sh (unchged)
Tom Russo 5,850 sh (unchged)
Samuel Isaly 548,000 sh (unchged)
Jim Simons Sold Out
Larry Robbins Sold Out
Kyle Bass Sold Out
John Keeley 51,580 sh (-8.09%)
Paul Tudor Jones 8,100 sh (-24.78%)
Louis Moore Bacon 38,678 sh (-51.65%)
Mario Gabelli 26,450 sh (-60.67%)
Scott Black 48,980 sh (-72.88%)
Steven Cohen 100 sh (-99.97%)
» More
2016

MYL Guru Trades in 2016

Samuel Isaly Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Mylan NV

John Keeley Comments on Mylan Labs - Apr 26, 2016

Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Keeley Funds Comments on Mylan N.V. - Feb 03, 2016

The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

David Einhorn Comments on Mylan - Jan 19, 2016

We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant.

We acknowledge eventual headwinds for the company’s branded EpiPen product, whichcould encounter competition from generics in late 2016. However, we see medium-termupside from a competitor recall, an announced share repurchase, and board review ofcorporate governance complaints. Ultimately, we expect MYL to earn close to $7 per share in2018, driven by a robust pipeline of respiratory, injectable and biologic drugs and by furthercapital deployment including share repurchases. We initiated our position at an average priceof $45.32, about 9x 2016 consensus EPS estimates. MYL shares ended the quarter at $54.07.

From David Einhorn (Trades, Portfolio)'s Green Light Capital fourth quarter 2015 shareholder letter.

Check out David Einhorn latest stock trades

Keeley Funds Comments on Mylan NV - Nov 03, 2015

The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative impact on the entire industry.





From the Keeley All-Cap Value Fund commentary on third quarter 2015.



Check out John Keeley latest stock trades

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Samuel Isaly Trades in Health Care Stocks in 1st Quarter Guru sells stakes in Health Net, Mylan, trims stake in Bristol-Myers Squibb
Samuel Isaly (Trades, Portfolio), manager of Eaton Vance Worldwide Health Sciences Fund, was an active investor in health care-related stocks long before government became involved in the sector. His transactions in the first quarter, ended Feb. 29, reflected that interest. Read more...
John Keeley Comments on Mylan Labs Guru stock highlight
Mylan Labs (NASDAQ:MYL), another detractor, announced a slightly weaker quarter than expected as well as the acquisition of European-based Meda, which appeared expensive in our opinion. We met with management at a recent investor conference and discussed their failed hostile takeover attempt of Perrigo (PRGO), their rebuffing of Teva Pharmaceutical’s simultaneous acquisition offer, and its acquisition of Meda. Even though we believe the stock is relatively cheap, we did not receive satisfactory responses to our questions; as such we elected to sell the position. Read more...
Keeley Funds Comments on Mylan N.V. Guru stock highlight
The Fund’s largest contributor during the quarter was Mylan N.V (NASDAQ:MYL) which rose over 34 percent and added 84 basis points of return to the Fund. Shares were initially weak following its failed bid to merge with rival Perrigo (NYSE:PRGO). We viewed the failed bid as a positive as we were skeptical of the synergies between the two companies. We increased our exposure to the stock during the weakness as we believe the shares are very cheap on a valuation basis. Read more...
David Einhorn Comments on Mylan Guru stock highlight
We initiated a position in Mylan (NASDAQ:MYL), a global generic pharmaceuticals company. MYLshares fell 29% in the first three quarters of 2015 and over 45% from their mid-year highsafter generics rival Teva abandoned a hostile takeover bid for the company. During the fall,the market became overly focused on a series of overhangs including potential earningsdilution from a proposed and ultimately failed buyout of Perrigo (a private-label OTC business); corporate governance concerns including an unusual takeover-defense mechanism;and widespread unease about the pharmaceutical sector amidst scrutiny of specialty pharmaceutical manufacturers like Valeant. Read more...
Vanguard Raises Stakes in Biogen, Mylan, Merck Fund buys no new stakes in 3rd quarter
As its name suggests, Vanguard Health Care Fund (Trades, Portfolio) is almost exclusively interested in health care companies. It bought no new stakes in the third quarter, but it did make additions to several existing stakes. Read more...
Keeley Funds Comments on Mylan NV Guru stock highlight.
The largest detractor during the quarter was in the health care sector after Mylan NV (NASDAQ:MYL) fell over 40 percent and cost the Fund 83 basis points in performance. The key development that pressured the stock was when rival TEVA Pharmaceutical (NYSE:TEVA) removed its takeover bid and instead acquired Allergan PLC’s (NYSE:AGN) generic business. Mylan remains interested in acquiring Perrigo (NYSE:PRGO) who prefers to remain independent. In addition, all of healthcare, and drug makers specifically, are seeing considerable selling pressure due to Valiant Pharmaceutical’s (NYSE:VRX) specialty pharmacy sales and Mylan does not use specialty pharmacies. Lastly, political rhetoric about price controls in health care is being bandied about by the Democratic frontrunner and those comments have had a negative Read more...
Alan Fournier Sells Nine Stakes in Second Quarter Divestitures are the most Fournier has recorded in years
Alan Fournier (Trades, Portfolio) founded Pennant Capital Management in 2001 and manages Pennant Master Fund, Pennant Windward Master Fund, Broadway Gate Master Fund Ltd.,and Pennant General Partner LLC. Today Pennant Capital Management is worth around $4 billion. Read more...
Sequoia Fund Comments on Perrigo Guru stock highlight
Saatvik Agarwal: Read more...
Kyle Bass Focuses on Fuel, Pharmaceutical Stocks in Second Quarter
If there was a theme to Kyle Bass (Trades, Portfolio)’ investment activity in the second quarter, the founder of Dallas-based Hayman Capital Management L.P., displayed an interest in fuel and pharmaceutical stocks. Not all of Bass’ transactions fit neatly into that category, of course, but many did, including most of the largest ones. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.64
MYL's P/E(ttm) is ranked lower than
52% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.10 vs. MYL: 25.64 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s P/E(ttm) Range Over the Past 10 Years
Min: 7.05  Med: 25.40 Max: 112.56
Current: 25.64
7.05
112.56
Forward P/E 7.87
MYL's Forward P/E is ranked higher than
83% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.85 vs. MYL: 7.87 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.64
MYL's PE(NRI) is ranked lower than
52% of the 536 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.01 vs. MYL: 25.64 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s PE(NRI) Range Over the Past 10 Years
Min: 7.05  Med: 26.35 Max: 200.11
Current: 25.64
7.05
200.11
Price/Owner Earnings (ttm) 23.19
MYL's Price/Owner Earnings (ttm) is ranked higher than
63% of the 261 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.99 vs. MYL: 23.19 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MYL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.09  Med: 31.26 Max: 2237.06
Current: 23.19
12.09
2237.06
P/B 2.19
MYL's P/B is ranked higher than
58% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. MYL: 2.19 )
Ranked among companies with meaningful P/B only.
MYL' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.67 Max: 7.02
Current: 2.19
0.64
7.02
P/S 2.29
MYL's P/S is ranked higher than
53% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.78 vs. MYL: 2.29 )
Ranked among companies with meaningful P/S only.
MYL' s P/S Range Over the Past 10 Years
Min: 0.41  Med: 1.82 Max: 4.71
Current: 2.29
0.41
4.71
PFCF 12.92
MYL's PFCF is ranked higher than
74% of the 194 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.93 vs. MYL: 12.92 )
Ranked among companies with meaningful PFCF only.
MYL' s PFCF Range Over the Past 10 Years
Min: 8.82  Med: 19.52 Max: 83.39
Current: 12.92
8.82
83.39
POCF 10.53
MYL's POCF is ranked higher than
71% of the 253 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.08 vs. MYL: 10.53 )
Ranked among companies with meaningful POCF only.
MYL' s POCF Range Over the Past 10 Years
Min: 6.13  Med: 12.43 Max: 40.9
Current: 10.53
6.13
40.9
EV-to-EBIT 21.57
MYL's EV-to-EBIT is ranked lower than
60% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.82 vs. MYL: 21.57 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.70 Max: 36.9
Current: 21.57
-10.7
36.9
EV-to-EBITDA 11.81
MYL's EV-to-EBITDA is ranked higher than
65% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. MYL: 11.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.00 Max: 23.3
Current: 11.81
-17.7
23.3
PEG 3.88
MYL's PEG is ranked lower than
70% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.88 vs. MYL: 3.88 )
Ranked among companies with meaningful PEG only.
MYL' s PEG Range Over the Past 10 Years
Min: 0.71  Med: 2.67 Max: 11.5
Current: 3.88
0.71
11.5
Shiller P/E 71.79
MYL's Shiller P/E is ranked lower than
71% of the 140 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.65 vs. MYL: 71.79 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s Shiller P/E Range Over the Past 10 Years
Min: 14.33  Med: 66.98 Max: 149.14
Current: 71.79
14.33
149.14
Current Ratio 1.57
MYL's Current Ratio is ranked lower than
69% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. MYL: 1.57 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 3.97 Max: 7.82
Current: 1.57
1.21
7.82
Quick Ratio 1.10
MYL's Quick Ratio is ranked lower than
71% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MYL: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 3.14 Max: 6.16
Current: 1.1
0.85
6.16
Days Inventory 131.47
MYL's Days Inventory is ranked lower than
60% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.44 vs. MYL: 131.47 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 136.05 Max: 168.24
Current: 131.47
88.95
168.24
Days Sales Outstanding 104.09
MYL's Days Sales Outstanding is ranked lower than
71% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.18 vs. MYL: 104.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.32  Med: 84.21 Max: 107.26
Current: 104.09
70.32
107.26
Days Payable 77.69
MYL's Days Payable is ranked higher than
53% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.90 vs. MYL: 77.69 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 44.56  Med: 72.50 Max: 101.21
Current: 77.69
44.56
101.21

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.25
MYL's Price/Projected FCF is ranked higher than
78% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.83 vs. MYL: 1.25 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.49 Max: 2.33
Current: 1.25
0.62
2.33
Price/DCF (Earnings Based) 2.40
MYL's Price/DCF (Earnings Based) is ranked lower than
81% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.39 vs. MYL: 2.40 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.23
MYL's Price/Median PS Value is ranked lower than
62% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. MYL: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 2.08 Max: 3.53
Current: 1.23
0.36
3.53
Price/Peter Lynch Fair Value 2.80
MYL's Price/Peter Lynch Fair Value is ranked lower than
80% of the 174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. MYL: 2.80 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.75  Med: 1.98 Max: 4.28
Current: 2.8
0.75
4.28
Earnings Yield (Greenblatt) (%) 4.63
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. MYL: 4.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.7  Med: 5.40 Max: 19
Current: 4.63
2.7
19
Forward Rate of Return (Yacktman) (%) 12.97
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. MYL: 12.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.7  Med: 14.90 Max: 31.7
Current: 12.97
7.7
31.7

More Statistics

Revenue(Mil) $9429
EPS $ 1.66
Beta1.32
Short Percentage of Float9.45%
52-Week Range $37.59 - 75.40
Shares Outstanding(Mil)490.69

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 10,909 12,736 13,406
EPS($) 4.93 5.65 6.26
EPS without NRI($) 4.93 5.65 6.26

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Mylan NV was incorporated in Netherlands on July 7, 2014. The Company along with its subsidiaries is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. It also operates a research and development network that delivers a robust product pipeline. The Company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Specialty segment engages in the development and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and has also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
John Keeley Comments on Mylan Labs Apr 26 2016 
Ackman to Testify About Valeant Before Senate Apr 26 2016 
Mawer's Investment Newsletter 1st Quarter Apr 15 2016 
Insiders Keep on Selling Facebook and Ford Apr 08 2016 
Buy Perrigo After a Big Selloff? Yes Apr 04 2016 
David Einhorn's Top 5 New Q4 Buys Feb 16 2016 
David Einhorn Rebounds – Somewhat Feb 09 2016 
Keeley Funds Comments on Mylan N.V. Feb 03 2016 
KEELEY All Cap Value Fund Commentary - 4th Quarter 2015 Feb 03 2016 

More From Other Websites
Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock? Apr 28 2016
Cramer: Papa's Got a Brand New Bag, and Leaves Perrigo Holding the Old One Apr 26 2016
I'm a 'fan' of Joe's: Fred Hassan Apr 26 2016
[$$] As Its CEO Leaves for Valeant, Perrigo Continues to Struggle Apr 25 2016
Cramer: Papa's Got a Brand New Bag, and Leaves Perrigo Holding the Old One Apr 25 2016
[$$] As Its CEO Leaves for Valeant, Perrigo Continues to Struggle Apr 25 2016
Valeant Infects Perrigo Apr 25 2016
Mylan (MYL) Stock Pressured by Perrigo Profit Warning Apr 25 2016
Perrigo shares tumble as CEO leaves for Valeant, guidance cut again Apr 25 2016
The guy who may take over Valeant is walking from crisis to crisis Apr 22 2016
[$$] Perrigo's Papa in talks to be Valeant's new patriarch Apr 22 2016
Mylan CEO to walk in Pittsburgh Pride Equality March Apr 22 2016
Mylan to Report First Quarter 2016 Financial Results on May 3, 2016 Apr 19 2016
MYLAN N.V. Files SEC form 8-K, Unregistered Sale of Equity Securities, Change in Directors or... Apr 14 2016
Mylan NV breached its 50 day moving average in a Bullish Manner : MYL-US : April 14, 2016 Apr 14 2016
IBB Large-Caps: Mylan Launches Generic Version of Lopressor Apr 13 2016
Mylan Launches First and Only Available Intermediate Dosage Strengths of Generic Lopressor® Tablets... Apr 11 2016
9 Large-Cap Stocks With Big Upside Potential From Deutsche Bank Apr 09 2016
How Does Perrigo Compare to Its Peers in Valuation? Apr 08 2016
Mylan to present at Meda’s Annual General Meeting Apr 07 2016
Billionaire John Paulson’s 13F Picks Post 13% Drop in Q1 Apr 06 2016
Drugmaker Perrigo expects $100 million boost from new Israeli plant Mar 02 2016
Business Highlights Feb 10 2016
Mylan offers to buy Swedish pharma firm Meda for $9.9 bn Feb 10 2016
Mylan to buy Sweden's Meda AB for $7.2 billion Feb 10 2016
Mylan misses Street 4Q forecasts Feb 10 2016
Mylan offers to buy Swedish pharma firm Meda for $9.9 bn Feb 10 2016
U.S. copy of GSK's Advair a step closer as Mylan files generic version Jan 12 2016
2016 Jan 06 Phosphagenics Initiates Arbitration Against Mylan Jan 06 2016
Phosphagenics Initiates Arbitration against Mylan Jan 06 2016
Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan's Over-the-Counter Business Nov 24 2015
Mylan Third Quarter 2015 Constant Currency Adjusted Total Revenues Increase 36% and Adjusted Diluted... Nov 23 2015
U.S. District Court Denies Perrigo's Motion for Preliminary Injunction Related to Certain Mylan... Nov 20 2015
Mylan Confirms Availability of EpiPen® (epinephrine injection) Auto-Injector for U.S. Patients... Nov 19 2015
Tel Aviv District Court Rules in Favor of Mylan Listing on Tel Aviv Stock Exchange Nov 19 2015
US STOCKS-U.S. stocks fall, with retail, technology leading rout Nov 13 2015
Big deal momentum may carry into 2016 for health care Nov 13 2015
Mylan's $35 bn bid for Perrigo fails Nov 13 2015
Perrigo to go it alone; shareholders reject $26B Mylan bid Nov 13 2015
Perrigo tumbles as shareholders reject Mylan offer Nov 13 2015
Shareholders of drugmaker Perrigo shut the door on Mylan and its $26B, hostile takeover bid Nov 13 2015
Mylan's $35 bn bid for Perrigo fails Nov 13 2015
Mylan's tender offer for Perrigo unlikely to succeed - sources Nov 12 2015
Mylan-targeted Perrigo held merger talks with Endo - sources Nov 12 2015
Perrigo Reaffirms Views on Mylan's Inadequate Offer; Maintains Strong Recommendation Shareholders... Nov 10 2015
Perrigo Issues Shareholder Letter Nov 09 2015
Mylan not relying on acquisitions if Perrigo bid fails -chairman Nov 04 2015
FTC approves Mylan's hostile bid for Perrigo with conditions Nov 03 2015
FTC clears Mylan's $27B proposed takeover of Perrigo Nov 03 2015
FTC approves Mylan's hostile bid for Perrigo with conditions Nov 03 2015
FTC approves hostile Mylan takeover of Perrigo with conditions Nov 03 2015
Perrigo Comments On Mylan's Presentation Oct 30 2015
Mylan profit beats as generic sales jump in North America and Europe Oct 30 2015
Mylan beats 3Q profit forecasts Oct 30 2015
U.S. FDA warns Novartis on manufacturing violations at two India plants Oct 28 2015
Perrigo CEO doesn't believe Mylan's hostile bid will succeed Oct 27 2015
Perrigo Taking Actions To Deliver Shareholder Value Far Superior To Mylan Offer Oct 22 2015
Irish takeover panel rejects Perrigo's request over Mylan offer Oct 13 2015
Paragraph IV Notice from Mylan Technologies Inc... Oct 05 2015
Exclusive - Perrigo under shareholder pressure to explore sale: sources Sep 29 2015
Perrigo urges shareholders to reject Mylan takeover offer Sep 17 2015
Perrigo Board Unanimously Rejects Mylan's Unsolicited Exchange Offer As Inadequate Sep 17 2015
Mylan opens $27.14 billion hostile bid for Perrigo Sep 15 2015
Mylan takes takeover bid to Perrigo shareholders Sep 14 2015
Mylan Statement in Response to FDA Warning Letter Relating to Certain Agila Facilities Sep 14 2015
Perrigo Announcement Regarding Unsolicited Offer From Mylan N.V. Sep 14 2015
Theravance Biopharma and Mylan Initiate Phase 3 Program for Revefenacin (TD-4208) for Treatment of... Sep 14 2015
Perrigo Responds to Misleading Letter from Mylan Executive Chairman Sep 10 2015
Mylan says it will launch $27.14B bid for Perrigo Sep 08 2015
Mylan takes takeover bid to Perrigo shareholders Sep 08 2015
Largest Dutch pension fund exits Mylan over death penalty concerns Aug 29 2015
Mylan shareholders approve hostile takeover Aug 28 2015
Mylan gets EU clearance for Perrigo clearance Jul 29 2015
Hikma to buy Boehringer's U.S. generic drug business for $2.65 bln Jul 28 2015
Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid Jul 27 2015
Teva to buy Allergan generic drug unit for $40.5 bn Jul 27 2015
Botox owner Allergan sells generic drugs unit to Teva for $41bn Jul 27 2015
Botox owner Allergan in talks to sell generic drugs unit to Teva for $45bn Jul 27 2015
Mylan foundation to block Israel's Teva hostile takeover bid Jul 23 2015
Teva to lift bid for Mylan: report Jul 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK